Skip to main content
. 2022 Mar 11;12:837589. doi: 10.3389/fonc.2022.837589

Figure 8.

Figure 8

TTFields disrupt cilia in patient samples ex vivo. (A) Ex vivo treatment of surgical resections. Biopsies were dissected and separated into immediate/acute fix, 24 h control or 24 TTFields treatment. Tissue was fixed, frozen, cryosectioned, and immunostained. Nuclei are labeled with DAPI. (B) Immunostaining of control section of a grade 1 subependymoma showed ARL13B+ cilia (arrowheads) extending from OFD1+ basal bodies (arrows). (C) TTFields-treated tissue section showed OFD1+ basal bodies (arrows) without obvious ARL13B+ cilia extensions. (D–F) Tissue from a malignant glioma from a 34-year-old male that was separated into immediate/acute fixation, 24-h control, or 24-h TTFields exposure. Tissues were fixed, cryosectioned, and immunostained for ARL13B (green) and gTub (red), and nuclei labeled with DAPI (white). ARL13B+ cilia (arrows) with gTUB+ basal bodies (arrowheads) are readily detected in acute (D) and 24-h control (E) but appeared blunted or generally absent in TTFields group (F). (G) Mean (+/− SEM) number of cilia/field (n = 12–13 fields/group) from samples in (D–F). **** p < 0.0001 (ANOVA). Scale bars (in µm) in (A) = 10.